PROCEPT BioRobotics Corporation $PRCT Position Increased by William Blair Investment Management LLC

Posted by George Bondi on May 26th, 2026

William Blair Investment Management LLC raised its position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT – Free Report) by 8.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 416,243 shares of the company’s stock after buying an additional 33,226 shares during the quarter. William Blair Investment Management LLC owned 0.74% of PROCEPT BioRobotics worth $13,095,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. DNB Asset Management AS purchased a new stake in PROCEPT BioRobotics during the third quarter valued at about $1,132,000. SG Americas Securities LLC lifted its stake in PROCEPT BioRobotics by 142.0% during the fourth quarter. SG Americas Securities LLC now owns 84,294 shares of the company’s stock valued at $2,652,000 after buying an additional 49,457 shares in the last quarter. Baillie Gifford & Co. lifted its stake in PROCEPT BioRobotics by 18.3% during the fourth quarter. Baillie Gifford & Co. now owns 1,015,978 shares of the company’s stock valued at $31,963,000 after buying an additional 157,147 shares in the last quarter. Prosight Management LP purchased a new stake in PROCEPT BioRobotics during the third quarter valued at about $2,748,000. Finally, C WorldWide Group Holding A S purchased a new stake in PROCEPT BioRobotics during the third quarter valued at about $5,354,000. 89.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on PRCT shares. Bank of America lowered shares of PROCEPT BioRobotics from a “neutral” rating to an “underperform” rating and reduced their price objective for the company from $38.00 to $20.00 in a research note on Thursday, February 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Tuesday, April 21st. Robert W. Baird started coverage on shares of PROCEPT BioRobotics in a research report on Friday, March 6th. They issued a “neutral” rating and a $30.00 price target for the company. Truist Financial decreased their price target on shares of PROCEPT BioRobotics from $47.00 to $30.00 and set a “buy” rating for the company in a report on Friday, February 27th. Finally, TD Cowen lowered their price objective on shares of PROCEPT BioRobotics from $50.00 to $34.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Eight investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, PROCEPT BioRobotics presently has an average rating of “Hold” and a consensus price target of $41.45.

Read Our Latest Stock Report on PROCEPT BioRobotics

Insider Buying and Selling

In related news, EVP Kevin Waters sold 6,721 shares of the stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $23.70, for a total value of $159,287.70. Following the transaction, the executive vice president owned 152,264 shares in the company, valued at approximately $3,608,656.80. This represents a 4.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Antal Rohit Desai bought 167,246 shares of PROCEPT BioRobotics stock in a transaction on Thursday, March 5th. The stock was acquired at an average price of $25.58 per share, with a total value of $4,278,152.68. Following the completion of the purchase, the director directly owned 167,246 shares of the company’s stock, valued at approximately $4,278,152.68. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have bought 426,262 shares of company stock worth $10,483,091 and have sold 23,229 shares worth $573,466. 6.60% of the stock is currently owned by corporate insiders.

PROCEPT BioRobotics Price Performance

PRCT opened at $29.00 on Tuesday. The stock has a fifty day moving average price of $25.45 and a 200 day moving average price of $28.62. The company has a current ratio of 6.73, a quick ratio of 5.51 and a debt-to-equity ratio of 0.15. PROCEPT BioRobotics Corporation has a 1 year low of $19.35 and a 1 year high of $66.85. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of -15.93 and a beta of 0.83.

PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) last issued its earnings results on Wednesday, April 29th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 27.70% and a negative net margin of 31.82%.The firm had revenue of $83.13 million during the quarter, compared to analyst estimates of $80.52 million. The business’s revenue for the quarter was up 20.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.45) earnings per share. Analysts forecast that PROCEPT BioRobotics Corporation will post -1.53 EPS for the current fiscal year.

PROCEPT BioRobotics Profile

(Free Report)

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.